Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Rx-to-OTC switch products reimbursed by 30% of HMOs -- Novartis report.

This article was originally published in The Tan Sheet

Executive Summary

Rx-TO-OTC SWITCH PRODUCT PURCHASES REIMBURSED BY 30% OF HMOs, according to the "Novartis Pharmacy Benefit Report: 1997 Trends & Forecasts." The report notes that while "almost 30% of the HMOs in this sample said they have continued to cover an Rx-to-OTC switch product after it changed status," 66% discontinue coverage for switched drugs.
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

PS087254

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel